[LCID Study Number: 20193055]
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non‐Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis
This study is being done to answer the following questions:
Does starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (OS) (time being alive) for patients with your type of cancer? Does additional treatment with chemotherapy following immunotherapy alone also improve overall survival?
We are doing this study because we want to find out whether either of these two usual approaches to treating your type of cancer is better or worse than the other. The usual approach is defined as care most people get for PD-L1 positive non-squamous non-small cell lung cancer.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3421